MX2013010446A - Regimenes de dosificacion para el tratamiento de la enfermedad de fabry. - Google Patents
Regimenes de dosificacion para el tratamiento de la enfermedad de fabry.Info
- Publication number
- MX2013010446A MX2013010446A MX2013010446A MX2013010446A MX2013010446A MX 2013010446 A MX2013010446 A MX 2013010446A MX 2013010446 A MX2013010446 A MX 2013010446A MX 2013010446 A MX2013010446 A MX 2013010446A MX 2013010446 A MX2013010446 A MX 2013010446A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- fabry disease
- dosing regimens
- subject matter
- disclosed subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01062—Glycosylceramidase (3.2.1.62)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451798P | 2011-03-11 | 2011-03-11 | |
| US201161578201P | 2011-12-20 | 2011-12-20 | |
| US201261596165P | 2012-02-07 | 2012-02-07 | |
| PCT/US2012/028260 WO2012125402A2 (en) | 2011-03-11 | 2012-03-08 | Dosing regimens for the treatment of fabry disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013010446A true MX2013010446A (es) | 2014-03-27 |
Family
ID=46831259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013010446A MX2013010446A (es) | 2011-03-11 | 2012-03-08 | Regimenes de dosificacion para el tratamiento de la enfermedad de fabry. |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20140219986A1 (enExample) |
| EP (2) | EP2683382B1 (enExample) |
| JP (6) | JP2014528901A (enExample) |
| KR (1) | KR20140011367A (enExample) |
| CN (2) | CN107088225A (enExample) |
| AU (6) | AU2012229330B2 (enExample) |
| CA (1) | CA2829947C (enExample) |
| CL (1) | CL2013002601A1 (enExample) |
| EA (1) | EA031874B1 (enExample) |
| ES (1) | ES2807502T3 (enExample) |
| HK (1) | HK1242998A1 (enExample) |
| MX (1) | MX2013010446A (enExample) |
| SG (2) | SG10201604757RA (enExample) |
| TW (3) | TW201740945A (enExample) |
| WO (1) | WO2012125402A2 (enExample) |
| ZA (1) | ZA201306735B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX351004B (es) | 2006-05-16 | 2017-09-26 | Nat Institutes Of Health | Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry. |
| WO2009102895A2 (en) | 2008-02-12 | 2009-08-20 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| US9580511B2 (en) | 2013-03-11 | 2017-02-28 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
| CN106687596A (zh) * | 2014-02-17 | 2017-05-17 | 葛兰素史密斯克莱知识产权发展有限公司 | 微生物学方法 |
| HUE061339T2 (hu) | 2014-03-19 | 2023-06-28 | Genzyme Corp | Targetáló csoportok helyspecifikus glikotechnikai átalakítása |
| US9675627B2 (en) * | 2014-04-14 | 2017-06-13 | Amicus Therapeutics, Inc. | Dosing regimens for treating and/or preventing cerebral amyloidoses |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| ES3067417T3 (en) | 2015-08-11 | 2026-05-21 | Cognoa Inc | Apparatus to determine developmental progress with artificial intelligence and user input |
| US11972336B2 (en) | 2015-12-18 | 2024-04-30 | Cognoa, Inc. | Machine learning platform and system for data analysis |
| EP3432882B1 (en) * | 2016-03-22 | 2021-09-01 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having the g9331a mutation in the gla gene |
| WO2018017721A1 (en) * | 2016-07-19 | 2018-01-25 | Amicus Therapeutics, Inc. | Treatment of fabry disease in ert-naïve and ert-experienced patients |
| CN118609834A (zh) | 2016-11-14 | 2024-09-06 | 科格诺亚公司 | 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置 |
| JP7324709B2 (ja) * | 2017-02-09 | 2023-08-10 | コグノア，インク． | デジタル個別化医療のためのプラットフォームとシステム |
| AU2018277756A1 (en) | 2017-05-30 | 2020-01-23 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| PL4062916T3 (pl) * | 2017-05-30 | 2025-03-17 | Amicus Therapeutics, Inc. | Leczenie pacjentów z chorobą Fabry’ego mających pewne mutacje |
| JP7066157B2 (ja) | 2017-06-14 | 2022-05-13 | 学校法人 明治薬科大学 | ファブリー病治療用医薬の組合せ物及びその利用 |
| EP4717319A3 (en) | 2018-02-06 | 2026-06-10 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in pregnant patients |
| LT3840753T (lt) | 2018-08-20 | 2024-11-11 | Amicus Therapeutics, Inc. | Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją |
| CN113873935B (zh) | 2019-03-22 | 2024-11-22 | 科格诺亚公司 | 个性化数字化治疗方法和装置 |
| JP7575401B2 (ja) | 2019-04-03 | 2024-10-29 | ジェンザイム・コーポレーション | 断片化が低減した抗アルファベータｔｃｒ結合ポリペプチド |
| US20220313670A1 (en) * | 2019-06-11 | 2022-10-06 | Amicus Therapeutics, Inc. | Methods Of Treating Fabry Disease In Patients Having Renal Impairment |
| KR20220044560A (ko) | 2019-08-07 | 2022-04-08 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
| WO2021046412A1 (en) | 2019-09-06 | 2021-03-11 | Cognoa, Inc. | Methods, systems, and devices for the diagnosis of behavioral disorders, developmental delays, and neurologic impairments |
| FI4114390T3 (fi) * | 2020-03-06 | 2025-03-07 | Amicus Therapeutics Inc | Menetelmiä fabryn taudin hoitamiseksi potilaissa, joilla on mutaatio gla-geenissä |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
| US20240120050A1 (en) * | 2022-10-07 | 2024-04-11 | Insight Direct Usa, Inc. | Machine learning method for predicting a health outcome of a patient using video and audio analytics |
| CN118488839A (zh) * | 2022-12-13 | 2024-08-13 | 阿米库斯治疗学公司 | 改善米加司他的药代动力学的方法 |
| US20240197706A1 (en) * | 2022-12-13 | 2024-06-20 | Amicus Therapeutics, Inc. | Methods of improving the pharmacokinetics of migalastat |
| TR2024011149A1 (tr) * | 2024-08-23 | 2026-03-23 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Mi̇galastat i̇çeren kapsül formülasyonlari |
| TR2024011147A1 (tr) * | 2024-08-23 | 2026-03-23 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Mi̇galastat i̇çeren kapsül formülasyonu |
| US20260188467A1 (en) * | 2024-12-27 | 2026-07-02 | Center for Social Dynamics, LLC | Parallel Processing Systems and Methods For Real-Time Multimodal Behavioral Classification Using Neural Networks With Dynamic Content Adaptation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4551177A (en) * | 1984-04-23 | 1985-11-05 | National Starch And Chemical Corporation | Compressible starches as binders for tablets or capsules |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| JP5589165B2 (ja) * | 2003-01-31 | 2014-09-17 | マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー | タンパク質欠損性障害の治療のための併用療法 |
| US7879354B2 (en) * | 2004-01-13 | 2011-02-01 | Mcneil-Ppc, Inc. | Rapidly disintegrating gelatinous coated tablets |
| CN100457106C (zh) * | 2005-06-15 | 2009-02-04 | 同济大学 | 1-脱氧野尻霉素在制备治疗糖尿病肾病药物中的应用 |
| MX351004B (es) * | 2006-05-16 | 2017-09-26 | Nat Institutes Of Health | Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry. |
| EP2142197A4 (en) * | 2007-03-30 | 2010-11-10 | Amicus Therapeutics Inc | METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES |
| AU2008245578A1 (en) * | 2007-04-26 | 2008-11-06 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| US20100291060A1 (en) * | 2007-08-29 | 2010-11-18 | Shire Human Genetic Therapies, Inc | Subcutaneous administration of alpha-galactosidase a |
-
2012
- 2012-03-08 WO PCT/US2012/028260 patent/WO2012125402A2/en not_active Ceased
- 2012-03-08 KR KR1020137026394A patent/KR20140011367A/ko not_active Ceased
- 2012-03-08 SG SG10201604757RA patent/SG10201604757RA/en unknown
- 2012-03-08 CN CN201611235913.7A patent/CN107088225A/zh active Pending
- 2012-03-08 EP EP12758017.3A patent/EP2683382B1/en active Active
- 2012-03-08 CA CA2829947A patent/CA2829947C/en active Active
- 2012-03-08 AU AU2012229330A patent/AU2012229330B2/en active Active
- 2012-03-08 ES ES12758017T patent/ES2807502T3/es active Active
- 2012-03-08 EA EA201301018A patent/EA031874B1/ru not_active IP Right Cessation
- 2012-03-08 US US14/004,335 patent/US20140219986A1/en not_active Abandoned
- 2012-03-08 SG SG2013067954A patent/SG193379A1/en unknown
- 2012-03-08 MX MX2013010446A patent/MX2013010446A/es unknown
- 2012-03-08 CN CN201280021877.8A patent/CN103974619B/zh active Active
- 2012-03-08 JP JP2013557862A patent/JP2014528901A/ja active Pending
- 2012-03-08 EP EP20160164.8A patent/EP3698792A1/en active Pending
- 2012-03-12 TW TW106126844A patent/TW201740945A/zh unknown
- 2012-03-12 TW TW101108345A patent/TWI624258B/zh not_active IP Right Cessation
- 2012-03-12 TW TW105118425A patent/TWI624259B/zh not_active IP Right Cessation
-
2013
- 2013-09-09 ZA ZA2013/06735A patent/ZA201306735B/en unknown
- 2013-09-10 CL CL2013002601A patent/CL2013002601A1/es unknown
-
2016
- 2016-06-28 AU AU2016204445A patent/AU2016204445B2/en active Active
-
2017
- 2017-03-01 JP JP2017038469A patent/JP2017132780A/ja active Pending
- 2017-10-12 US US15/782,431 patent/US20180153999A1/en not_active Abandoned
-
2018
- 2018-02-23 HK HK18102615.1A patent/HK1242998A1/zh unknown
- 2018-03-07 AU AU2018201637A patent/AU2018201637A1/en not_active Abandoned
-
2019
- 2019-10-10 JP JP2019186952A patent/JP2020033360A/ja active Pending
-
2020
- 2020-03-02 US US16/806,404 patent/US20200268890A1/en not_active Abandoned
- 2020-03-09 AU AU2020201715A patent/AU2020201715A1/en not_active Abandoned
-
2021
- 2021-02-08 JP JP2021018456A patent/JP2021098697A/ja not_active Withdrawn
-
2022
- 2022-05-05 AU AU2022203011A patent/AU2022203011A1/en not_active Abandoned
-
2023
- 2023-03-22 JP JP2023045001A patent/JP2023093448A/ja active Pending
- 2023-07-17 US US18/222,745 patent/US20240115708A1/en active Pending
-
2024
- 2024-07-31 AU AU2024205251A patent/AU2024205251A1/en active Pending
-
2025
- 2025-10-24 JP JP2025179237A patent/JP2026035578A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012125402A3 (en) | Dosing regimens for the treatment of fabry disease | |
| CY1124135T1 (el) | Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε | |
| PH12012501364A1 (en) | Antibody formulation and therapeutic regimens | |
| PH12014501997A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| GB201111485D0 (en) | Drug composition and its use in therapy | |
| PT2470199T (pt) | Terapia de substituição enzimática com escaladas de dose para tratamento de deficência em esfingomielinase ácida | |
| PH12014500468A1 (en) | Heterocyclic compounds and uses thereof | |
| MX2013009764A (es) | Moduladores de receptores canabinoides. | |
| NZ702469A (en) | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | |
| IL260078B (en) | Therapy used to treat Gaucher disease | |
| MX356317B (es) | Tratamiento de síntomas asociados a gastroparesia femenina. | |
| MX2015005993A (es) | Composiciones y metodos para el tratamiento de displasia ectodermica. | |
| MX2013010947A (es) | Complejos de galio, composiciones farmacéuticas y métodos de uso. | |
| AP3390A (en) | Therapeutic vaccination against active tuberculosis | |
| EP2703006A4 (en) | USE OF A CALCINEURIN 1 REGULATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ENHANCED NF-KB ACTIVITY | |
| UA70710U (ru) | Способ профилактики рецидивов аллергодерматозов у больных с вторичными иммунодефицитными состояниями | |
| EP2692351A4 (en) | ACTIVE FRACTION OF PAULLINIA CUPANA WITH IMPROVED EFFICACY AGAINST TEMPTATION, PROCESS FOR PREPARING AN ACTIVE FRACTION, USE THEREOF, PHARMACEUTICAL COMPOSITION, MEDICAMENTS AND TREATMENT FOR TREATMENT | |
| UA65037U (ru) | Способ лечения взрослых больных с соматоформными расстройствами | |
| UA72002U (ru) | Способ коррекции показателей системы фагоцитирующих макрофагов у больных туберкулезом легких | |
| UA70775U (ru) | Способ лечения менингококцемии у детей | |
| UA64067U (ru) | Способ лечения больных синдромом стивена-джонсона | |
| UA65038U (ru) | Способ лечения больных послеродовыми психозами | |
| UA52520U (ru) | Способ лечения нарушений функционального состояния кишечника у новорожденных и детей младенческого возраста | |
| UA59700U (ru) | Способ лечения метаболического синдрома | |
| UA69683U (ru) | Способ лечения больных стеатогепатитом |